Germany's IDT could apply for COVID-19 vaccine approval in late 2021: CEO
German Health Minister Jens Spahn and Juergen Betzing, CEO of German vaccine maker IDT Biologika visit their vaccine production in Dessau Rosslau, Germany, November 23, 2020. Hendrik Schmidt/Pool via REUTERS
Germany's IDT Biologika plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year and hopes to be able to apply for approval in 2021, its Chief Executive said on Monday.
"If all clinical tests are successful, we could apply for an accelerated approval at the end of 2021," said Juergen Betzing at a news conference in Dessau.
German Health Minister Jens Spahn and Juergen Betzing, CEO of German vaccine maker IDT Biologika visit their vaccine production in Dessau Rosslau, Germany, November 23, 2020. Hendrik Schmidt/Pool via REUTERS
(Reporting by Thomas Seythal and Kirsti Knolle)
German Health Minister Jens Spahn and Saxony-Anhalt's Prime Minister Reiner Haseloff visit the production of German vaccine maker IDT Biologika in Dessau Rosslau, Germany, November 23, 2020, as the spread of the coronavirus disease (COVID-19) continues. Hendrik Schmidt/Pool via REUTERSStaff works at the vaccine maker IDT Biologika production in Dessau Rosslau, Germany, November 23, 2020, as the spread of the coronavirus disease (COVID-19) continues. Hendrik Schmidt/Pool via REUTERSJuergen Betzing, CEO of German vaccine maker IDT Biologika, shareholder Carsten Klocke, German Health Minister Jens Spahn and Saxony-Anhalt's Prime Minister Reiner Haseloff pose for a pictures after visiting the production of German vaccine maker IDT Biologika in Dessau Rosslau, Germany, November 23, 2020, as the spread of the coronavirus disease (COVID-19) continues. Hendrik Schmidt/Pool via REUTERS
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
